Gilead Sciences, Inc. (NASDAQ:GILD) Stake Lowered by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 863,563 shares of the biopharmaceutical company's stock after selling 3,407 shares during the period. Nomura Asset Management Co. Ltd. owned 0.07% of Gilead Sciences worth $79,767,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in GILD. Norges Bank purchased a new stake in Gilead Sciences during the 4th quarter worth about $1,789,254,000. Wellington Management Group LLP grew its holdings in shares of Gilead Sciences by 50.9% during the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock worth $2,900,921,000 after buying an additional 11,665,593 shares in the last quarter. Pacer Advisors Inc. grew its holdings in shares of Gilead Sciences by 723.3% during the fourth quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock worth $594,370,000 after buying an additional 5,653,075 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $207,340,000. Finally, Point72 Asset Management L.P. boosted its position in Gilead Sciences by 350.1% during the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company's stock worth $193,274,000 after acquiring an additional 1,793,145 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares in the company, valued at $19,977,938.37. The trade was a 9.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders sold 302,785 shares of company stock worth $30,503,250. Corporate insiders own 0.16% of the company's stock.

Gilead Sciences Stock Down 0.5 %

Shares of NASDAQ GILD traded down $0.58 during midday trading on Tuesday, reaching $111.47. 2,410,650 shares of the company's stock were exchanged, compared to its average volume of 8,562,145. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The business's fifty day moving average price is $105.88 and its two-hundred day moving average price is $95.20. The stock has a market capitalization of $138.82 billion, a PE ratio of 301.08, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were issued a dividend of $0.79 per share. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.83%. The ex-dividend date was Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is currently 854.05%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on GILD. BMO Capital Markets boosted their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Bank of America raised their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, Wells Fargo & Company raised their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $105.12.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.